[go: up one dir, main page]

NO3052752T3 - - Google Patents

Info

Publication number
NO3052752T3
NO3052752T3 NO14789648A NO14789648A NO3052752T3 NO 3052752 T3 NO3052752 T3 NO 3052752T3 NO 14789648 A NO14789648 A NO 14789648A NO 14789648 A NO14789648 A NO 14789648A NO 3052752 T3 NO3052752 T3 NO 3052752T3
Authority
NO
Norway
Application number
NO14789648A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO3052752T3 publication Critical patent/NO3052752T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
NO14789648A 2013-02-22 2014-09-24 NO3052752T3 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361767947P 2013-02-22 2013-02-22

Publications (1)

Publication Number Publication Date
NO3052752T3 true NO3052752T3 (fr) 2018-06-16

Family

ID=50151346

Family Applications (2)

Application Number Title Priority Date Filing Date
NO14789648A NO3052752T3 (fr) 2013-02-22 2014-09-24
NO2022004C NO2022004I1 (no) 2013-02-22 2022-02-01 abrocitinib, or a pharmaceutically acceptable salt thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2022004C NO2022004I1 (no) 2013-02-22 2022-02-01 abrocitinib, or a pharmaceutically acceptable salt thereof

Country Status (47)

Country Link
US (3) US9035074B2 (fr)
EP (2) EP3290421B1 (fr)
JP (2) JP6145179B2 (fr)
KR (1) KR101787858B1 (fr)
CN (2) CN105008362B (fr)
AP (1) AP2015008664A0 (fr)
AR (1) AR094857A1 (fr)
AU (1) AU2014220357B2 (fr)
BR (1) BR112015019634B1 (fr)
CA (1) CA2900703C (fr)
CL (1) CL2015002303A1 (fr)
CR (1) CR20150395A (fr)
CU (1) CU24275B1 (fr)
CY (3) CY1119502T1 (fr)
DK (2) DK3290421T3 (fr)
DO (1) DOP2015000206A (fr)
EA (1) EA027879B1 (fr)
ES (2) ES2647525T3 (fr)
FR (1) FR22C1006I2 (fr)
GE (1) GEP201606600B (fr)
HR (2) HRP20171599T2 (fr)
HU (3) HUE037192T2 (fr)
IL (1) IL240132B (fr)
LT (3) LT3290421T (fr)
LU (1) LUC00261I2 (fr)
MA (1) MA38347A1 (fr)
MD (1) MD4735C1 (fr)
ME (2) ME02904B (fr)
MX (1) MX374338B (fr)
MY (1) MY177476A (fr)
NL (1) NL301155I2 (fr)
NO (2) NO3052752T3 (fr)
NZ (1) NZ710411A (fr)
PE (1) PE20151764A1 (fr)
PH (1) PH12015501779B1 (fr)
PL (2) PL3290421T3 (fr)
PT (2) PT3290421T (fr)
RS (2) RS58245B1 (fr)
SG (1) SG11201505816UA (fr)
SI (2) SI3290421T1 (fr)
TN (1) TN2015000355A1 (fr)
TR (1) TR201902525T4 (fr)
TW (1) TWI507408B (fr)
UA (1) UA111804C2 (fr)
UY (1) UY35337A (fr)
WO (1) WO2014128591A1 (fr)
ZA (1) ZA201505454B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2605652T3 (pl) 2010-08-18 2018-04-30 Samumed, Llc Diketony i hydroksyketony jako aktywatory szlaku sygnalizacji kateninowej
AU2014209141B2 (en) 2013-01-24 2018-05-10 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mTOR inhibitors
PE20151721A1 (es) 2013-02-22 2015-12-07 Samumed Llc Y-dicetonas como activadores de la ruta de senalizacion de wnt/b-catenina
EP3290421B1 (fr) * 2013-02-22 2019-01-02 Pfizer Inc Combinaison de dérivés de pyrrolo-[2,3-d]pyrimidine et un ou plusieurs principes supplémentaires en tant qu'inhibiteurs des janus kinases (jak)
JP6585158B2 (ja) 2014-08-12 2019-10-02 ファイザー・インク ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体
KR102165385B1 (ko) 2014-08-20 2020-10-15 사뮤메드, 엘엘씨 피부 노화 및 주름의 치료 및 예방을 위한 감마-디케톤
WO2016192563A1 (fr) * 2015-05-29 2016-12-08 南京明德新药研发股份有限公司 Inhibiteur de la janus kinase
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CA3251507A1 (en) 2015-10-16 2025-05-21 Abbvie Inc Use of a solid dosage form comprising (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide for treating rheumatoid arthritis
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN106831779B (zh) * 2015-11-28 2019-07-19 南昌弘益药业有限公司 一类jak激酶抑制剂的新化合物
WO2017143014A1 (fr) * 2016-02-16 2017-08-24 Brian Kim Inhibiteurs de jak et leurs utilisations
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
CN108794480A (zh) * 2017-04-28 2018-11-13 天津药物研究院有限公司 吡咯并嘧啶类化合物、其制备方法和用途
PT3762368T (pt) 2018-03-08 2022-05-06 Incyte Corp Compostos de aminopirazina diol como inibidores de pi3k-y
WO2020010003A1 (fr) 2018-07-02 2020-01-09 Incyte Corporation DÉRIVÉS D'AMINOPYRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE PI3K-γ
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
IL279926B2 (en) * 2018-07-06 2023-12-01 Pfizer Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof
MX2021005334A (es) * 2018-11-05 2021-06-23 Avista Pharma Solutions Inc Compuestos quimicos.
CN111499641B (zh) * 2019-01-30 2021-06-04 格格巫（珠海）生物科技有限公司 一种jak抑制剂及其制备方法
KR102820235B1 (ko) 2019-02-15 2025-06-16 화이자 인코포레이티드 결정질 피리미디닐-3,8-다이아자바이사이클로[3.2.1]옥타닐메타논 화합물 및 이의 용도
WO2020182159A1 (fr) 2019-03-14 2020-09-17 上海华汇拓医药科技有限公司 Inhibiteur de kinase jak, son procédé de préparation et ses applications dans le domaine de la médecine
WO2020261041A1 (fr) * 2019-06-27 2020-12-30 Glenmark Life Sciences Limited Procédé pour la préparation d'abrocitinib
ES3019413T3 (en) * 2019-09-11 2025-05-20 Pfizer Treatment of hidradenitis suppurativa with a jak inhibitor
KR20220088699A (ko) 2019-09-27 2022-06-28 디스크 메디슨, 인크. 골수섬유증 및 관련 상태의 치료 방법
WO2021198980A1 (fr) 2020-04-04 2021-10-07 Pfizer Inc. Procédés de traitement de la maladie à coronavirus 2019
CN113637018A (zh) 2020-04-27 2021-11-12 苏州晶云药物科技股份有限公司 磺酰胺类化合物的晶型及其制备方法
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
US20230219963A1 (en) * 2020-05-28 2023-07-13 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives
TW202227434A (zh) * 2020-09-08 2022-07-16 瑞士商葛德瑪控股公司 新穎jak抑制劑化合物、其合成方法及其用途
CA3191598A1 (fr) * 2020-09-11 2022-03-17 Gilles Ouvry Nouveaux composes inhibiteurs de jak, leur procede de synthese et leur utilisation
CN116847850A (zh) 2021-02-02 2023-10-03 辉瑞公司 治疗慢性手部湿疹的给药方案
KR20230019801A (ko) * 2021-08-02 2023-02-09 한국화학연구원 신규한 피롤로 피리미딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 대사성 간질환의 예방 또는 치료용 약학적 조성물
CN118255769A (zh) * 2022-12-28 2024-06-28 格格巫（珠海）生物科技有限公司 一种立体异构体的制备方法及中间体
ES2993658B2 (es) * 2023-06-27 2025-07-02 Moehs Iberica Sl (3-(metil(7h-pirrolo[2,3-d]pirimidin-4-il)amino)ciclobutilo)carbamato de bencilo o una sal del mismo, procedimiento para su preparacion y su uso en la sintesis de abrocitinib
WO2025008772A2 (fr) 2023-07-06 2025-01-09 Pfizer Ireland Pharmaceuticals Procédé de fabrication amélioré et intermédiaires pour un composé pyrrolo[2,3-d]pyrimidine et leur utilisation
ES3040374A1 (es) 2024-04-30 2025-10-30 Moehs Iberica Sl Cocristales de N-{cis-3-[metil(7H-pirrolo[2,3-d]pirimidin-4-il)amino]ciclobutil}propano-1-sulfonamida

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
EP0674641B1 (fr) 1992-12-17 1999-03-03 Pfizer Inc. Pyrrolopyrimidines en tant qu'antagonistes du facteur liberateur de corticotrophine (crf)
JPH06329674A (ja) 1993-05-20 1994-11-29 Teijin Ltd ４―置換シクロヘキシルアミノ―ピロロ［２，３―ｄ］ピリミジン
JPH06329675A (ja) 1993-05-20 1994-11-29 Teijin Ltd ４―置換アルキルアミノ―ピロロ［２，３―ｄ］ピリミジン誘導体
JPH08134068A (ja) 1994-11-02 1996-05-28 Teijin Ltd ４―置換アルキルアミノ―ピロロ［２，３―ｄ］ピリミジン誘導体
US6051578A (en) 1996-02-12 2000-04-18 Pfizer Inc. Pyrazolopyrimidines for treatment of CNS disorders
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
RS50087B (sr) * 1998-06-19 2009-01-22 Pfizer Products Inc., Pirolo (2,3-d) pirimidin jedinjenja
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
EP1040831A3 (fr) 1999-04-02 2003-05-02 Pfizer Products Inc. Utilisation d'antagonistes du facteur de libération de la corticotropine pour la prévention de la mort subite
EP1175421A1 (fr) 1999-04-30 2002-01-30 Neurogen Corporation Derives 9h-pyrimido[4,5-b]indoles: ligands specifiques de crf1
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
CZ303875B6 (cs) 1999-12-10 2013-06-05 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidinová sloucenina a farmaceutická kompozice s jejím obsahem
EP1244668B1 (fr) 2000-01-07 2006-04-05 Universitaire Instelling Antwerpen Derives de purine, procede de preparation et utilisation de ces derniers
EA006153B1 (ru) 2000-06-26 2005-10-27 Пфайзер Продактс Инк. СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИММУНОДЕПРЕССАНТОВ
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
ATE446298T1 (de) 2001-11-30 2009-11-15 Osi Pharm Inc Verbindungen, die für adenosin a1 und a3 rezeptoren spezifisch sind, und deren anwendungen
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
WO2004032834A2 (fr) 2002-10-04 2004-04-22 Merck & Co., Inc. Inhibiteurs de thrombine
EP1572649A2 (fr) 2002-11-21 2005-09-14 Pfizer Products Inc. Derives de 3-amino-piperadine et leurs procedes de preparation
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
MX2008001334A (es) * 2005-07-29 2008-03-24 Pfizer Prod Inc Derivados de pirrolo [2,3-d]pirimidina, sus intermedios y sintesis.
JP2007091649A (ja) 2005-09-29 2007-04-12 Taisho Pharmaceut Co Ltd ピリミジン誘導体及びその使用に関連する治療方法
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EA200870385A1 (ru) 2006-03-29 2009-04-28 Фолдркс Фармасьютикалз, Инк. Ингибирование токсичности альфа-синуклеина
WO2008089307A2 (fr) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Méthodes et compositions utilisés dans le traitement de la douleur, de l'inflammation et du cancer
US20080200458A1 (en) 2007-01-18 2008-08-21 Joseph Barbosa Methods and compositions for the treatment of body composition disorders
JP2011503103A (ja) 2007-11-07 2011-01-27 フォールドアールエックス ファーマシューティカルズ インコーポレーティッド タンパク質輸送の調節方法
AU2008326184A1 (en) 2007-11-08 2009-05-14 Pfizer Inc. Cyclobutyl carboxylic acid derivatives
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
PT2384326E (pt) * 2008-08-20 2014-06-09 Zoetis Llc Compostos de pirrolo[2,3-d]pirimidina
AP2011005611A0 (en) 2008-09-18 2011-04-30 Pfizer Ltd Amide compounds useful in therapy.
EP2488524B1 (fr) * 2009-10-15 2013-07-03 Pfizer Inc. Derives de pyrrolo[2,3-d] pyrimidine
HUE033099T2 (en) 2009-12-01 2017-11-28 Abbvie Inc Novel tricyclic compounds
JP5739446B2 (ja) 2009-12-18 2015-06-24 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
KR20140015162A (ko) 2010-01-12 2014-02-06 에프. 호프만-라 로슈 아게 트라이사이클릭 헤테로사이클릭 화합물, 조성물 및 이의 사용 방법
WO2011104652A2 (fr) 2010-02-24 2011-09-01 Pfizer Inc. Compositions vétérinaires
PT2592933T (pt) 2010-07-16 2017-05-23 Gaweco Anderson Inibidores de mif e suas utilizações
EP2593425B1 (fr) 2010-07-16 2018-10-17 Agios Pharmaceuticals, Inc. Compositions thérapeutiquement actives et méthode d'utilisation correspondante
BR112013013659B8 (pt) 2010-12-03 2024-02-27 Epizyme Inc Compostos moduladores de enzimas epigenéticas, composição farmacêutica compreendendo ditos compostos e usos da dita composição farmacêutica para tratar câncer, câncer hematológico ou leucemia
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
WO2012169649A1 (fr) 2011-06-07 2012-12-13 Dainippon Sumitomo Pharma Co., Ltd. Dérivé d'indazole et pyrrolopyridine et utilisation pharmaceutique de celui-ci
JP2013010719A (ja) 2011-06-30 2013-01-17 Dainippon Sumitomo Pharma Co Ltd ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途
SMT201800497T1 (it) * 2011-12-21 2018-11-09 Shanghai hengrui pharmaceutical co ltd Derivato di pirrolo ad anello eteroarilico a sei elementi, relativo metodo di preparazione, e relativi usi medicinali
US20140018361A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
KR20150028299A (ko) 2012-07-20 2015-03-13 조에티스 엘엘씨 야누스 키나제 (ｊａｋ) 억제제 투여요법
JP2014133739A (ja) 2012-12-12 2014-07-24 Dainippon Sumitomo Pharma Co Ltd インダゾール誘導体またはピロロピリジン誘導体からなる医薬
EP3290421B1 (fr) * 2013-02-22 2019-01-02 Pfizer Inc Combinaison de dérivés de pyrrolo-[2,3-d]pyrimidine et un ou plusieurs principes supplémentaires en tant qu'inhibiteurs des janus kinases (jak)
JP6585158B2 (ja) 2014-08-12 2019-10-02 ファイザー・インク ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体

Also Published As

Publication number Publication date
US9545405B2 (en) 2017-01-17
EA027879B1 (ru) 2017-09-29
AP2015008664A0 (en) 2015-08-31
CL2015002303A1 (es) 2015-12-18
LT2958921T (lt) 2017-11-27
RS58245B1 (sr) 2019-03-29
GEP201606600B (en) 2017-01-10
IL240132A0 (en) 2015-09-24
JP2016509049A (ja) 2016-03-24
HRP20190152T1 (hr) 2019-03-22
MD4735C1 (ro) 2021-07-31
HK1213881A1 (zh) 2016-07-15
KR101787858B1 (ko) 2017-10-18
CN105008362B (zh) 2017-06-06
PE20151764A1 (es) 2015-12-03
PH12015501779A1 (en) 2015-12-02
RS56503B1 (sr) 2018-02-28
HUS2200003I1 (hu) 2022-02-28
PL3290421T3 (pl) 2019-05-31
CN107089985A (zh) 2017-08-25
DK3290421T3 (en) 2019-03-18
DOP2015000206A (es) 2016-02-15
LTC2958921I2 (fr) 2024-03-25
IL240132B (en) 2020-09-30
NZ710411A (en) 2017-11-24
LTPA2022502I1 (fr) 2022-03-10
AU2014220357A1 (en) 2015-08-06
MA38347A1 (fr) 2017-10-31
WO2014128591A1 (fr) 2014-08-28
SI2958921T1 (sl) 2017-12-29
US20150246048A1 (en) 2015-09-03
NL301155I2 (nl) 2022-02-23
PT2958921T (pt) 2017-11-20
EP2958921B1 (fr) 2017-09-20
CR20150395A (es) 2015-09-23
UA111804C2 (uk) 2016-06-10
CU24275B1 (es) 2017-10-05
UY35337A (es) 2014-09-30
ZA201505454B (en) 2016-07-27
LT3290421T (lt) 2019-02-25
TR201902525T4 (tr) 2019-03-21
HUE037192T2 (hu) 2018-08-28
MD20150073A2 (ro) 2016-01-31
NO2022004I1 (no) 2022-02-01
SG11201505816UA (en) 2015-09-29
CA2900703C (fr) 2017-11-28
EP3290421B1 (fr) 2019-01-02
JP6145179B2 (ja) 2017-06-07
MX2015010928A (es) 2015-10-29
LUC00261I2 (fr) 2025-04-25
EP2958921A1 (fr) 2015-12-30
FR22C1006I1 (fr) 2022-03-25
TN2015000355A1 (fr) 2017-01-03
CN107089985B (zh) 2019-06-07
SI3290421T1 (sl) 2019-03-29
KR20150109434A (ko) 2015-10-01
TWI507408B (zh) 2015-11-11
US9549929B2 (en) 2017-01-24
HRP20171599T2 (hr) 2018-11-16
AU2014220357B2 (en) 2017-04-27
CA2900703A1 (fr) 2014-08-28
CN105008362A (zh) 2015-10-28
BR112015019634B1 (pt) 2022-09-20
HRP20171599T1 (hr) 2017-12-01
US20140243312A1 (en) 2014-08-28
TW201443055A (zh) 2014-11-16
US20150225408A1 (en) 2015-08-13
PH12015501779B1 (en) 2015-12-02
MX374338B (es) 2025-03-06
FR22C1006I2 (fr) 2023-01-27
US9035074B2 (en) 2015-05-19
CY1119502T1 (el) 2018-03-07
HUE041778T2 (hu) 2019-05-28
MY177476A (en) 2020-09-16
MD4735B1 (ro) 2020-12-31
EA201591255A1 (ru) 2016-03-31
AR094857A1 (es) 2015-09-02
ES2713052T3 (es) 2019-05-17
EP3290421A1 (fr) 2018-03-07
CY2022003I1 (el) 2022-03-24
CY2022003I2 (el) 2022-03-24
PT3290421T (pt) 2019-03-01
JP2017165762A (ja) 2017-09-21
ME03301B (fr) 2019-07-20
DK2958921T3 (da) 2017-11-06
BR112015019634A2 (pt) 2019-12-17
ES2647525T3 (es) 2017-12-22
CU20150078A7 (es) 2016-01-29
PL2958921T3 (pl) 2018-01-31
CY1121468T1 (el) 2020-05-29
ME02904B (fr) 2018-04-20
NL301155I1 (fr) 2021-12-22

Similar Documents

Publication Publication Date Title
AP2016009275A0 (fr)
BR112015007533A2 (fr)
BR102016010778A2 (fr)
BR112014017733A2 (fr)
BR112014018502A2 (fr)
BR112014017739A2 (fr)
BR112014019326A2 (fr)
BR112014018480A2 (fr)
BR112014018516A2 (fr)
BR112014020341A2 (fr)
BR112014017855A2 (fr)
BR112014017765A2 (fr)
BR112014017669A2 (fr)
BR112014021878A2 (fr)
BR112015023235A2 (fr)
BR112014018468A2 (fr)
BR112014017901A2 (fr)
BR112014019204A2 (fr)
BR112014018207A2 (fr)
BR112015015948A2 (fr)
BR112014017722A2 (fr)
BR112014017653A2 (fr)
BR112014018578A2 (fr)
BR112014018483A2 (fr)
BR112014017794A2 (fr)